Covid Antibodies Endure Over Six Months in China Trial Subjects

Ref: Bloomberg
  • A top Chinese scientist┬ásays the amount of COVID-19 antibodies in trial subjects who received China's experimental vaccines remained high six months after the first shots, reported Bloomberg.

  • China now has at least 10 vaccine candidates in clinical trials, with four in Phase III testing around the world.

  • CanSino Biologics, which is co-developing a coronavirus vaccine with the Chinese military, was the first in the world to administer an experimental vaccine into healthy people in March, although Zeng Guang, chief scientist of the Chinese Center for Disease Control and Prevention,┬ádid not specify which vaccine candidate he was referring to.

  • Zeng said the high levels detected in volunteers who took part in the earliest clinical trials suggest the vaccines are effective and can provide immunity against SARS-CoV-2 for an extended period of time, though final-stage testing results still need to be evaluated.